Analysis of preferential drug provision for patients with diabetes mellitus in the Stavropol Region

The aim. To study the quantitative characteristics of the implementation of drug provision for beneficiaries with diabetes mellitus (DM) in the Stavropol Region in the period from 2020 to 2024.

Materials and methods. The regulatory legal basis of the study was made up of legislative acts of the federal and regional levels on the organization of preferential drug provision (PDP). Clinical and epidemiological monitoring of DM was carried out according to the data of the State Register of DM for the Stavropol Region, data from the Regional Endocrinological Dispensary (Stavropol Region, Russia), as well as reports from executive authorities.

Results. According to the clinical and epidemiological monitoring of DM in the Russian Federation in 2024, the prevalence of DM in the Stavropol Region did not exceed the average Russian indicators (rating 36). A decrease in the number of federal beneficiaries and an increase in the number of regional beneficiaries (with a predominance of DM type II) was noted. 10 municipalities where about 60% of patients with DM live were identified. Therapy for patients with DM type I is based on insulin therapy for 100% of patients. Therapy for patients with DM type II includes the use of insulin for 14,140 (20.63%) patients, oral hypoglycemic agents for 53,404 (77.88%) patients, and dietary adjustments for 1,025 (1.49%) people. Since 2024, in accordance with changes in the legislation of the Stavropol Region, all patients with DM are provided from general funds of the regional budget, with the exception of federal beneficiaries in Lermontov, who are provided at the expense of the program for the provision of necessary medicines (PNMs). The structure of expenditures from the federal and regional budgets for the purchase of funds for the treatment of DM is presented. The dynamics of the growth of expenses per one beneficiary with DM is shown. It should be noted that in 2024 there was an equalization of the amount of expenses per one federal and regional beneficiary.

Conclusion. The results obtained can be used by other researchers to take solutions to improve the availability of drug provision for beneficiaries with DM both in the Stavropol Region and in other subjects of the Russian Federation.

1. Zapariy NS, Asriyan AYu, Letskaya OA, Begma IV, Kuzina IV. Characteristics of the General Contingent of Disabled People Due to Diabetes Mellitus Among the Adult Population for the Period 2017–2021. Bulletin of the Russian Society of Professionals in Medical and Social Expertise, Rehabilitation and Rehabilitational Industry. 2023;(3):48–55. DOI: 10.17238/issn1999-2351.2023.3.48-55

2. Dedov II, Shestakova MV, Vikulova OK, Zheleznyakova AV, Isakov MA, Sazonova DV, Mokrysheva NG. Diabetes mellitus in the Russian Federation: dynamics of epidemiological indicators according to the Federal Register of Diabetes Mellitus for the period 2010–2022. Diabetes mellitus. 2023;26(2):104–23. DOI: 10.14341/DM13035

3. Dedov II, Shestakova MV, Vikulova OK, Zheleznyakova AV, Isakov MA, Serkov AA, Mokrysheva NG. Diabetes mellitus in the Russian Federation: dynamics of clinical and epidemiological indicators according to the Federal Register of diabetes mellitus for the period 2009-2023. Innovative technologies in Endocrinology (ITE 2024): Collection of abstracts of the V (XXX) National Congress of Endocrinologists with International participation. Moscow: Limited Liability Company "Printing House "Printmaker"; 2024. P. 30–31. DOI: 10.14341/Cong21-24.05.24-30-31. Russian

4. Ruina OV, Borisov VI, Stroganov AB, Melnichenko OV, Pyatunin KV, Papushina NO. Pharmacoeconomic analysis of therapy of complicated diabetes mellitus in a hospital. Modern problems of science and education. 2020;(6):115. DOI: 10.17513/spno.30219

5. Dedov II, Kalashnikova MF, Belousov DY, Kolbin AS, Rafalskiy VV, Cheberda AE, Kantemirova MA, Zakiev VD, Fadeyev VV. Cost-of-Illness Analysis of Type 2 Diabetes Mellitus in the Russian Federation: Results from Russian multicenter observational pharmacoepidemiologic study of diabetes care for patients with type 2 diabetes mellitus (FORSIGHT-Т2DM). Diabetes mellitus. 2017;20(6):403–419. DOI: 10.14341/DM9278

6. Batrakova IA. Analysis of the incidence of socially significant diseases in the Russian Federation for 2018-2023. Young Scientist. 2024;(11(510)):180–2. EDN: VXQDRE. Russian

7. Galushin PV, Galushina EN. Cluster analysis of socially significant diseases in the Russian Federation. Vestnik NSUEM. 2023;(1):169–183. DOI: 10.34020/2073-6495-2023-1-169-183

8. Dolgova EM, Ponomarev AD, Shigaev NN, Ivlieva ES, Mirieva ID. Trends in the incidence of certain socially significant diseases in the adults and children population of the Saratov region. National Health Care (Russia). 2023;4(3):27–32. DOI: 10.47093/2713-069X.2023.4.3.27-32

9. Ovechkina NI, Shmarikhina ES. Incidence of Socially Significant Diseases in the Context of Studying the Demographic Security of the Country. Vestnik NSUEM. 2019;(4):208–219. DOI: 10.34020/2073-6495-2019-4-208-219

10. Voropinova OA, Germanova YuI, Malkina LV. Status and dynamic of socially significant diseases in the regions of the North Caucasus Federal District. Medical news of the North Caucasus. 2014;9(1):63–66. DOI: 10.14300/mnnc.2014.09018

11. Levina Ya.V., Kurakov D.A. Actual issues of free drug provision in Russia. Medicinal Bulletin. 2023;24(2(90)):11–14. EDN: SYFUKY. Russian

12. Linnik SA, Shvachko SA, Tumenko EE. Subsidized Pharmaceutical Provision for patients in the Federal Districts and subjects of the Russian Federation using the example of the most common diseases. Manager Zdravoohranenia. 2023;2:40–9. DOI: 10.21045/1811-0185-2023-2-40-49

13. Gogova MA, Ayro IN, Mikaelyan MF. Analysis of the implementation of drug supply programs for federal and regional beneficiaries suffering from type 2 diabetes mellitus in the Kabardino-Balkarian Republic. Medical & pharmaceutical journal “Pulse”. 2023;25(12):104–10. DOI: 10.26787/nydha-2686-6838-2023-25-12-104-110

14. Petrukhina IK, Yagudina RI, Ryazanova TK, Kurkin VA, Egorova AV, Loginova LV, Khusainova AI, Blinkova PR. On the implementation of regional programs of subsidized drug provision in the subjects of the Russian Federation. Zdravookhranenie Rossiiskoi Federatsii. 2022;66(2):108–15. DOI: 10.47470/0044-197X-2022-66-2-108-115

15. Menshikova LI, Endovitskaya YV, Ladygin AY, Gezey NF, Shkerskaya NY. Problems of realization of the right of patients with diabetes mellitus to preferential medicine supply in the far north regions. Current problems of health care and medical statistics. 2022;(3):628–41. DOI: 10.24412/2312-2935-2022-3-628-641

16. Samoylova AV, Vovk EG, Yagudina RI, Serpik VG, Gavrilina NI. Modern state of regional preferential provision of medicines for citizens in the federal subjects of the Russian Federation. Vestnik Roszdravnadzora. 2025;3:29–35. EDN: UOKEGG

17. Kharina IA, Dzhuparova IA. Opinion of medical and pharmaceutical professionals on the quality of pharmaceutical care for patients with diabetes mellitus in the Novosibirsk region: a comparative sociological study. Patient-Oriented Medicine and Pharmacy. 2024;2(2):35–42. DOI: 10.37489/2949-1924-0048

18. Kurkin DV, Makarova EV, Zvereva VI, Makarova AR, Bakulin DA, Marincheva OV, Gorbunova YuV, Kolosov YuA, Krysanov IS, Koryanova KN, Galkina DA, Osadchenko NA, Drai RV, Makarenko IE, Shuvaeva AS. Dynamics of turnover of sugar-lowering drugs in the retail segment of the pharmaceutical market from 2020 to 2024. Pharmacy & Pharmacology. 2025;13(2):84–97. DOI: 10.19163/2307-9266-2025-13-2-84-97

19. Petrukhina IK, Lazarev AM, Ryazanova TK, Lebedev PA, Gladunova EP, Glembotskaya GT. The sale of medicines used for diabetes mellitus treatment in retail segment of Russian pharmaceutical market. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2025;18(1):14–21. DOI: 10.17749/2070-4909/farmakoekonomika.2024.281

20. Antsiferov MB, Koteshkova OM, Dukhareva OV. Modern Approaches to Non-Insulin Therapy of Patients with Type 2 Diabetes Mellitus. Doctor.Ru. 2021;20(2):30–9. DOI: 10.31550/1727-2378-2021-20-2-30-39

21. Ametov AS, Pashkova EYu, Gadzhiev VR. Double diabetes: modern challenge. Doctor.Ru. 2024;23(4):7–14. DOI: 10.31550/1727-2378-2024-23-4-7-14

22. Petrukhina IK, Khusainova AI. Study of the specifics of the implementation of drug provision for regional beneficiaries suffering from diabetes mellitus in the subjects of the Russian Federation. Current Drug Supply Management. 2022;9(3):89–90. DOI: 10.30809/solo.3.2022.32

23. Dedov II, Shestakova MV, Vikulova OK, Zheleznyakova AV, Isakov MA, Kutakova DV, Mokrysheva NG. Epidemiology and key clinical and therapeutic indicators of diabetes mellitus in Russian Federation according to the World Health Organization's strategy goals. Diabetes mellitus. 2025;28(1):4–17. DOI: 10.14341/DM13292

24. Zhdanova EA, Volynkina AP, Kolimbet LP, Petrova TN, Khodarina YuV. Clinical and epidemiological characteristics of diabetes mellitus and its complications in the Voronezh region. Russian Medical Inquiry. 2023;7(9):561–565. DOI: 10.32364/2587- 6821-2023-7-9-1

25. Аntsiferov MB, Demidov NA. Register of patients with diabetes mellitus in Moscow: possibilities of analysis and control of clinical and epidemiological parameters. City Healthcare. 2020;1(2):8–19. DOI: 10.47619/2713-2617.zm.2020.v1i2

26. Hossain MJ, Al-Mamun M, Islam MR. Diabetes mellitus, the fastest growing global public health concern: Early detection should be focused. Health Sci Rep. 2024;7(3):e2004. DOI: 10.1002/hsr2.2004

27. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants. Lancet. 2024;404(10467):2077–2093. DOI: 10.1016/S0140-6736(24)02317-1. Erratum in: Lancet. 2025;405(10485):1146. DOI: 10.1016/S0140-6736(25)00620-8

28. Begun DN, Bulycheva EV, Borshchuk EL, Choloyan SB, Gubaidullina LR. Morbidity of the population with leading nosological forms of endocrine pathology. Manager Zdravoohranenia. 2025;4:134–146. DOI: 10.21045/1811-0185-2025-4-134-146

29. Savina A. trends in incidence of disorders of the endocrine system in the Russian adults. Social aspects of Population Health. 2021;67(4):6. DOI: 10.21045/2071-5021-2021-67-4-6

30. Frolova OA, Tafeeva EA, Frolov DN, Yangirova EKh. Retrospective analysis of the incidence rate of the population in the Republic of Tatarstan with diseases of the endocrine system. Problems of Social Hygiene, Public Health and History of Medicine. 2022;30(5):795–800. DOI: 10.32687/0869-866X-2022-30-5-795-800

31. Shulaev AV, Shaidullina MR, Valeeva FV, Khisamiev RSh, Shikaleva AA, Shavaliev RF. Clinical and statistical analysis of the incidence of endocrine system diseases, eating and metabolic disorders among children and adolescents in the Republic of Tatarstan. The Bulletin of Contemporary Clinical Medicine. 2021;14(6):82–93. DOI: 10.20969/VSKM.2021.14(6).82-93

32. Kalininskaya A.A., Rybakov I.A., Vasiliev M.D., Balzamova L.A. Analysis of diabetes incidence in the Russian Federation and prevention of patients’ disability. Manager Zdravoohranenia. 2025;8:109–17. DOI: 10.21045/1811-0185-2025-8-109-117